Journal
JOURNAL OF NEUROCHEMISTRY
Volume 123, Issue 1, Pages 73-83Publisher
WILEY
DOI: 10.1111/j.1471-4159.2012.07876.x
Keywords
a7; allosteric modulator; desensitization; nicotinic acetylcholine receptor; up-regulation
Categories
Funding
- Danish Medical Research Council
- Lundbeck Foundation
- NOVO Nordisk Foundation
- Danish Ministry of Science, Technology and Innovation
Ask authors/readers for more resources
Long-term treatment with nicotine or selective a7 nicotinic acetylcholine receptor (nAChR) agonists increases the number of a7 nAChRs and this up-regulation may be involved in the mechanism underlying the sustained procognitive effect of these compounds. Here, we investigate the influence of type I and II a7 nAChR positive allosteric modulators (PAMs) on agonist-induced a7 nAChR up-regulation. We show that the type II PAMs, PNU-120596 (10 mu M) or TQS (1 and 10 mu M), inhibit up-regulation, as measured by protein levels, induced by the a7 nAChR agonist A-582941 (10 nM or 10 mu M), in SH-EP1 cells stably expressing human a7 nAChR, whereas the type I PAMs AVL-3288 or NS1738 do not. Contrarily, neither type I nor II PAMs affect 10 mu M nicotine-induced receptor up-regulation, suggesting that nicotine and A-582941 induce up-regulation through different mechanisms. We further show in vivo that 3 mg/kg PNU-120596 inhibits up-regulation of the a7 nAChR induced by 10 mg/kg A-582941, as measured by [125I]-bungarotoxin autoradiography, whereas 1 mg/kg AVL-3288 does not. Given that type II PAMs decrease desensitization of the receptor, whereas type I PAMs do not, these results suggest that receptor desensitization is involved in A-582941-induced up-regulation. Our results are the first to show an in vivo difference between type I and II a7 nAChR PAMs, and demonstrate an agonist-dependent effect of type II PAMs occurring on a much longer time scale than previously appreciated. Furthermore, our data suggest that nicotine and A-582941 induce up-regulation through different mechanisms, and that this confers differential sensitivity to the effects of a7 nAChR PAMs. These results may have implications for the clinical development of a7 nAChR PAMs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available